Only 18.0 % ( n = 55 ) of sampled organizations had adopted acamprosate for treating AUDs , and adoption was positively associated with accreditation , having a physician on staff , receiving information about acamprosate via pharmaceutical representatives , and learning about this medication from other treatment providers .